Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Sakar Healthcare Limited

NSE: SAKARPharmaceuticalsASM stage 1

Share price

₹1,011.50

+0.91% close of 9 Oct 2026

Market cap ₹2,225 CrP/E 61.8

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

70

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹2,225 Cr

P/E ratio

61.8

P/B ratio

6.9

ROCE

12.4%

ROE

9.8%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹1,188.4052-week low ₹351.50

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 43.8% over the past year, and 18.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 24.4% to 28.1% over the last four years.

Whether it grew faster than its sector

It grew 18.0% a year against a sector median of 13.1% — 4.9 percentage points faster.

Room to re-rate, or risk of de-rating

At 61.8× earnings it costs 2.6× the market, which pays 24.1× across 2199 companies we can price. Its own industry sits at 31.2×, across 5 companies. It is against its own five-year median of 42.8×, the 89th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.8 times its growth rate, on earnings growth of 34%.

Profit growthPrice per ₹1 profitPer 1% growth
Sakar Healthcare Limited — this one34%/yr61.8×₹1.8
Torrent Pharmaceuticals22%/yr79.4×₹3.6
Zydus Lifesciences32%/yr23.2×₹0.72
Laurus Labs Limited4%/yr100.5×₹25.1
Cipla10%/yr29.4×₹2.9
Dr Reddy's Laboratories-4%/yr31.2×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 77 of 130 on returns, 27 of 127 on growth, 35 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 12.4% on capital, ahead of 41% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹176 crore of cash from the business but spent ₹298 crore on plant and equipment, ₹122 crore more than it made; the gap was from shareholders — borrowings did not rise. And the profit is real: of every 100 rupees it reported over 7 years, about 193 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back more slowly than it used to: it went from being paid 11 days before it paid its own suppliers to waiting 45 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue rose 38.4% year on year and profit rose 105.7% in Q1 FY27.

Announced 24 Jul 2026 · Consolidated · Unaudited

Revenue

₹73 Cr

Revenue vs last year

+38.4%

Revenue vs last quarter

+2.6%

Net profit

₹10 Cr

Profit vs last year

+105.7%

Profit vs last quarter

-6.5%

Net margin

14.1%

EPS

₹4.62

Earnings call transcript · 29 Jul 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹2,225 Cr
Prev close
₹1,011.50
52w High
₹1,230
52w Low
₹346
Enterprise value
₹2,246 Cr
Beta
0.8
Price CAGR 1y
181.0%
Price CAGR 3y
44.0%
Price CAGR 5y
44.0%
Price CAGR 10y
—

Ratios

Return on assets
6.2%
PEG ratio
1.8
P/E ratio
61.8
P/B ratio
6.9
EV / EBITDA
29.2
Industry P/E
37.6
ROCE
12.4%
ROCE 5y average
9.8%
ROE
9.8%
Debt / Equity
0.2
Interest coverage
6.0
Dividend yield
0.0%
ROE 3y average
8.0%
ROE last year
10.0%

Annual P&L

Annual revenue
₹251 Cr
Annual profit
₹30 Cr
Operating margin
27.0%
Net profit margin
12.0%
EBITDA margin
27.5%
Sales growth 3y
23.6%
Sales growth 5y
21.4%
Profit growth 3y
34.0%
Profit growth 5y
23.0%
EPS
₹13.7
Sales growth TTM
44.0%
Profit growth TTM
82.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹73 Cr
Profit latest quarter
₹10 Cr
YoY quarterly sales growth
38.4%
YoY quarterly profit growth
100.0%
OPM latest quarter
29.1%

Balance Sheet

Book Value
₹147
Face Value
₹10.0
Total debt
₹71 Cr
Total cash
₹0 Cr
Borrowings
₹71 Cr
Reserves / Equity
13.7

Cash Flow

Operating cash flow
₹49 Cr
Free cash flow
₹21 Cr
FCF yield
0.6%
Net cash flow
₹0 Cr

Shareholding

Promoter holding
52.5%
FII holding
12.1%
DII holding
11.4%
Public holding
24.0%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,758.2533.34,21,8630.902,901.26.015,299.910.520.5
Divi's Lab.9,425.0084.02,50,2040.31902.065.53,080.027.822.0
Torrent Pharma.4,631.2079.01,76,1560.81566.05.84,921.054.915.2
Zydus Lifesci.1,115.6022.91,11,2820.09990.2-35.18,017.022.021.1
Laurus Labs2,019.5599.81,09,1190.10362.1125.52,026.329.117.8
Cipla1,301.2029.41,05,1200.98785.6-39.27,119.32.315.5
Mankind Pharma2,393.2046.398,8500.04574.129.64,030.612.913.5
Sakar Healthcare1,010.5062.32,2480.0010.3120.173.038.412.4
Median414.0034.12,1230.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales39343743414343505358707173
Expenses30252832303132354046524552
Material Cost262930393640
Change in Inventories-110.200.80-3.01-7.40-5.45
Purchases of Stock-in-Trade000000
Employee Cost167.558.349.891311
Other Expenses3.963.537.466.333.545.69
Operating Profit99911111212161311192621
OPM %23272425262727312420263729
Other Income2101000001102
Exceptional items (within Other Income)000000
Interest2222121422222
Depreciation5445555566667
Profit before tax4435555655111815
Tax %28133135496178131563929
Net Profit3423255655101110
EPS in Rs1.491.700.951.431.112.212.062.622.102.044.614.954.62
Diluted EPS in Rs2.662.112.034.594.964.62

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales8395128133153178252272
Expenses637299100115128182195
Material Cost95133
Change in Inventories-13-9.41
Purchases of Stock-in-Trade00
Employee Cost3239
Other Expenses1421
Operating Profit2023293338506977
OPM %2424232525282728
Other Income21253123
Exceptional items (within Other Income)-0.050
Interest223688.537.867
Depreciation78101518212425
Profit before tax1213191716224049
Tax %21192024271923
Net Profit1011151312183036
EPS in Rs6.436.848.906.705.377.971416
Diluted EPS in Rs7.9514
Dividend Payout %0000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
21%
3 years
24%
TTM
44%

Compounded profit growth

10 years
—
5 years
23%
3 years
34%
TTM
82%

Stock price CAGR

10 years
—
5 years
44%
3 years
44%
1 year
181%

Return on equity

10 years
—
5 years
8%
3 years
8%
Last year
10%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital15161719222222
Reserves6683110154241264302
Borrowings174393119798671
Other Liabilities17374744474386
Total Liabilities115178268336389415481
Fixed Assets6669205267314309326
CWIP1349160174
Investments0073000
Other Assets366055607490151
Total Assets115178268336389415481

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity19153633243449
Cash from Investing Activity-22-47-90-74-52-31-28
Cash from Financing Activity332554127-3-21
Net Cash Flow-0-0-000-0-0
Free Cash Flow-4-32-62-49-353.2921

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days36484060506373
Inventory Days921126976121193207
Days Payable4614114912912093153
Cash Conversion Cycle8319-39751163127
Working Capital Days311-11-6295245
ROCE %131297912

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters545353535354545353535353
FIIs141414141314141313131312
DIIs111111111111111111111111
Public212223232322222222232324
No. of Shareholders7,2997,0017,3867,3137,8678,5988,6088,1157,5657,0699,58014,734

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +186.2% (₹353.45 → ₹1,011.50)Brick size ₹65.54 (fixed)Bricks 13
₹500₹750₹1,012Feb '26Jul '26
Price moved up one brickPrice moved down one brickLast close ₹1,011.50 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

20.92inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Sakar Healthcare Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Artemether API
  • Cephalosporin key starting materials (7-ACA, 7-ADCA, GCLE)
  • Diclofenac API
  • Oncology API intermediates (cytotoxic)
  • Paracetamol API

Sells to

  • Accord Healthcare · oncology formulations for Europe (Intas UK)
  • Baxter International · CDMO injectables
  • Emcure Pharmaceuticals Limited · CDMO formulations (oncology; injectables/oral solids)
  • Ferring Pharmaceuticals · CDMO EU-GMP injectables
  • Glenmark Pharmaceuticals Limited · CDMO formulations (oncology tech-transfer; injectables/oral solids)
  • Intas Pharmaceuticals · CDMO formulations (oncology)
  • Merck · CDMO pharmaceutical formulations
  • Torrent Pharmaceuticals · CDMO pharmaceutical formulations
  • Zydus Lifesciences · CDMO pharmaceutical formulations (oncology / injectables / oral solids)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE732S01012

Plants

  • Lyophilized Injectables Unit · Bavla, Gujarat
  • Oncology API Manufacturing Unit · Bavla, Gujarat
  • Oncology FDF Manufacturing Unit · Bavla, Gujarat
  • Plant-1 – Liquid Orals · Changodar (Sanand), Gujarat
  • Plant-2 – Beta-Lactam Oral Solids · Changodar (Sanand), Gujarat
  • Plant-3 – SVP Liquid Injectables · Changodar (Sanand), Gujarat
  • Plant-4 – Dry Powder Injections · Changodar (Sanand), Gujarat

News impact

Big market events that reach Sakar Healthcare Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

  • daily-prices repair: 33 rows from NSE's archive (replace 24, delete 1, insert 8), 2017-06-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Jun 2017

Bulk & block deals

DateWhoBought / soldSharesPrice
15 May 2026STELLAR WEALTH PARTNERS INDIA FUND I LPBUY1,95,000₹664.58

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
10 Sep 2026Aarsh S. Shah · PromoterSELL80,0007.81
10 Sep 2026Aarsh S. Shah · PromoterSELL35,0003.46
10 Sep 2026Aarsh S. Shah · PromoterSELL5,1000.51
13 Aug 2026Aarsh S. Shah · PromoterSELL10,0000.96
13 Aug 2026Aarsh S. Shah · PromoterSELL1,0250.10
7 Aug 2026Aarsh S. Shah · PromoterSELL15,0001.39

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.